Carl Erwin Ware

US Patent:

7030080, Apr 18, 2006

Filed:

Nov 7, 2001

Appl. No.:

10/040281

Inventors:

Jeffrey Browning - Brookline MA, US
Carl F. Ware - Riverside CA, US

Assignee:

Biogen, Inc. - Cambridge MA
University of California - Oakland CA

International Classification:

A61K 38/00

US Classification:

514 2, 4241431, 4241341, 514 8

Abstract:

This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23. D7 cells. This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes comprising multiple subunits of lymphotoxin-β. These proteins and complexes are useful in holding LT-α formed within the cell on the cell surface where the LT-α/LT-β complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-α/LT-β complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-β.

US Patent:

20070116668, May 24, 2007

Filed:

Dec 20, 2005

Appl. No.:

11/313230

Inventors:

Jeffrey Browning - Brookline MA, US
Carl Ware - Riverside CA, US

International Classification:

C07K 14/52
A61K 38/19
C07H 21/04
C12P 21/02

US Classification:

424085100, 435069500, 435320100, 435325000, 530351000, 536023500

Abstract:

This invention relates to lymphotoxin-β, a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23.D7 cells. This invention also relates to complexes formed between lymphotoxin-β and other peptides such as lymphotoxin-α and to complexes comprising multiple subunits of lymphotoxin-β. These proteins and complexes are useful in holding LT-α formed within the cell on the cell surface where the LT-α/LT-β complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-α/LT-β complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-β.

US Patent:

56610041, Aug 26, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/484272

Inventors:

Jeffrey Browning - Brookline MA
Carl F. Ware - Riverside CA

Assignee:

Biogen, Inc. - Cambridge MA
University of California - Oakland CA

International Classification:

C12N 1500
C12N 1511
C12N 1585

US Classification:

435 691

Abstract:

This invention relates to lymphotoxin-. beta. , a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23. D7 cells. This invention also relates to complexes formed between lymphotoxin-. beta. and other peptides such as lymphotoxin-. alpha. and to complexes comprising multiple subunits of lymphotoxin-. beta. These proteins and complexes are useful in holding LT-. alpha. formed within the cell on the cell surface where the LT-. alpha. /LT. beta. complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-. alpha. /LT-. beta. complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-. beta.

US Patent:

57959641, Aug 18, 1998

Filed:

Jun 6, 1995

Appl. No.:

8/467070

Inventors:

Jeffrey Browning - Brookline MA
Carl F. Ware - Riverside CA

Assignee:

Biogen, Inc. - Cambridge MA
University of California - Oakland CA

International Classification:

C07K 1446
C07K 1452
C07K 14435

US Classification:

530351

Abstract:

This invention relates to lymphotoxin-. beta. , a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PMA) stimulated T cell hybridoma II-23. D7 cells. This invention also relates to complexes formed between lymphotoxin-. beta. and other peptides such as lymphotoxin-. alpha. and to complexes comprising multiple subunits of lymphotoxin-. beta. These proteins and complexes are useful in holding LT-. alpha. formed within the cell on the cell surface where the LT-. alpha. /LT-. beta. complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-. alpha. /LT-. beta. complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-. beta.

US Patent:

56701497, Sep 23, 1997

Filed:

Jun 6, 1995

Appl. No.:

8/476489

Inventors:

Jeffrey Browning - Brookline MA
Carl F. Ware - Riverside CA

Assignee:

Biogen, Inc. - Cambridge MA
The University of California - Oakland CA

International Classification:

A61K 39395

US Classification:

4241301

Abstract:

This invention relates to lymphotoxin-. beta. , a lymphocyte membrane type protein. This protein is found on the surface of a number of cells, including phorbol ester (PNA) stimulated T cell hybridoma II-23. D7 cells. This invention also relates to complexes formed between lymphotoxin-. beta. and other peptides such as lymphotoxin-. alpha. and to complexes comprising multiple subunits of lymphotoxin-. beta. These proteins and complexes are useful in holding LT-. alpha. formed within the cell on the cell surface where the LT-. alpha. /LT-. beta. complex may act as an inflammation regulating agent, a tumor growth inhibiting agent, a T cell inhibiting agent, a T cell activating agent, an autoimmune disease regulating agent, or an HIV inhibiting agent. Furthermore, the antitumor activity of the LT-. alpha. /LT-. beta. complex may be delivered to tumor cells by tumor infiltrating lymphocytes (TILs) transfected with the gene for LT-. beta.